Results 31 to 40 of about 20,522 (204)
Inhibition of cholesterol absorption by the combination of dietary plant sterols and ezetimibe
Consumption of plant sterols and treatment with ezetimibe both reduce cholesterol absorption in the intestine. However, the mechanism of action differs between the two treatments, and the consequences of combination treatment are unknown.
Lily Jakulj +5 more
doaj +1 more source
A simple, sensitive and specific liquid chromatographyâtandem mass spectrometry method was developed for simultaneous quantification of ezetimibe and simvastatin in rat plasma.
Sireesha R. Karanam +4 more
doaj +1 more source
Background: Real-world data on use of PCSK9 inhibitors (PCSK9-Is), with or without statins and/or ezetimibe, and associated outcomes, can inform more effective prescribing.
Jessica Eloso +8 more
doaj +1 more source
Ezetimibe use and mortality after myocardial infarction: A nationwide cohort study
Background: The inhibition of intestinal cholesterol absorption by ezetimibe improves outcomes after myocardial infarction (MI), yet real-world data on ezetimibe is scarce. We studied the usage of ezetimibe and association with outcome after MI. Methods:
Ville Kytö, Aleksi Tornio
doaj +1 more source
Adding ezetimibe to statin therapy: latest evidence and clinical implications
Background: Statins are the hypolipemic treatment of choice for hyperlipidemia with confirmed atherosclerotic cardiovascular disease (ASCVD) protective effect, proven even in normolipemic patients.
Marija Vavlukis, Ana Vavlukis
core +1 more source
Kajian literatur efektivitas dan efek samping kombinasi simvastatin dan ezetimibe pada pasien dislipidemia [PDF]
Dislipidemia adalah kelainan metabolisme lipida ditandai dengan kenaikan kadar kolesterol total, Low Density Lipoprotein (LDL), dan trigliserida serta penurunan kadar High Density Lipoprotein (HDL).
Rahmawati, Eka Yustia
core
Ezetimibe: Use, costs, and adverse events in Australia
Aim: To analyze the subsidized use and reported adverse events of ezetimibe, used to lower cholesterol, in Australia over the 11 years following its inclusion on the Pharmaceutical Benefits Scheme (PBS) in 2004.
Martin, JH +4 more
core +1 more source
Serious drug-induced liver disease secondary to ezetimibe [PDF]
Ezetimibe is the first member of a new family of lipid-lowering drugs that inhibits uptake of dietary and biliary cholesterol. It was approved by the FDA in 2002 for hypercholesterolemia alone or in combination with statins.
Girbau, Anna +4 more
core +1 more source
Abstract DNA‐encoded libraries (DELs) enable large‐scale screening for hit identification, but accessing sp3‐rich, three‐dimensional chemotypes beyond flat, aromatic scaffolds remains challenging. Multicomponent reactions (MCRs) assemble such complexity from simple building blocks in a single step, and reaction‐engineering strategies have extended on ...
Jimin Moon +3 more
wiley +1 more source
The effect of anti‐seizure medications on exposure to statins: A systematic review and meta‐analysis
Abstract Objectives Antiseizure medications (ASMs) can reduce the efficacy of statin treatment, partly due to reduction in statin concentrations. In this systematic review and network meta‐analysis (NMA), we compared the effects of ASMs and the prototypical enzyme inducer rifampin on statin exposure.
Sharon Valiyev Huino +5 more
wiley +1 more source

